Go Deep
Rossari Biotech Limited
Rossari Biotech Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 25,082 | 15.1 | 1.70 | 0.33 | 409.80 |
| Oct 2026 | 24,401 | 15.1 | 1.70 | 0.33 | 409.80 |
Rossari Biotech Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 6,972,000,000.0 | 6,848,620,000.0 | 5,816,800,000.0 | 5,437,160,000.0 |
| Net Profit | 350,950,000.0 | 459,670,000.0 | 327,740,000.0 | 335,960,000.0 |
| EPS | 6.3 | 8.3 | 5.9 | 6.1 |
Rossari Biotech Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 23,898,180,000.0 | 20,714,570,000.0 | 18,251,880,000.0 | 16,513,170,000.0 | — |
| Net Profit | 1,492,130,000.0 | 1,363,780,000.0 | 1,306,890,000.0 | 1,072,570,000.0 | — |
| EPS | 26.9 | 24.7 | 23.7 | 19.5 | — |
Rossari Biotech Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 22,887,920,000.0 | 18,961,840,000.0 | 15,721,510,000.0 | 13,675,650,000.0 | — |
| Total Liabilities | 9,554,430,000.0 | 7,107,350,000.0 | 5,244,230,000.0 | 4,523,990,000.0 | — |
| Total Equity | 13,333,490,000.0 | 11,854,490,000.0 | 10,477,280,000.0 | 9,151,660,000.0 | — |
Owes vs Owns
Rossari Biotech Limited owed ₹0.42 for every ₹1 it owned in Mar 2026, up from ₹0.33 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.42× | 0.37× | 0.33× | 0.33× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Rossari Biotech Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 4.9%Receivables 24.4%Inventory 17.7%Fixed assets (tangible) 33.0%Intangible assets 9.8%Long-term investments 1.2%Other assets 9.1%
How it's funded — Mar 2026
Short-term debt 13.7%Long-term debt 4.1%Payables 14.1%Other liabilities 9.8%Shareholders' equity 58.3%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 112.9 | 105.1 | 69.5 | 148.5 |
| Receivables | 557.4 | 474.5 | 425.1 | 353.7 |
| Inventory | 404.5 | 355.1 | 282.3 | 188.5 |
| Fixed assets (tangible) | 755.6 | 555.7 | 425.1 | 334.5 |
| Intangible assets | 223.9 | 244.8 | 262.9 | 274.6 |
| Long-term investments | 27.0 | 26.3 | 25.1 | 25.0 |
| Other assets | 207.4 | 134.7 | 82.1 | 42.9 |
| Liabilities & equity | ||||
| Short-term debt | 313.7 | 87.9 | 72.5 | 39.0 |
| Long-term debt | 94.3 | 100.0 | 33.3 | 34.9 |
| Payables | 323.5 | 286.3 | 219.1 | 181.0 |
| Other liabilities | 224.0 | 236.4 | 199.5 | 197.5 |
| Shareholders' equity | 1,333.3 | 1,185.4 | 1,047.7 | 915.2 |
| Net tangible assets | 1,109.4 | 940.6 | 784.9 | 640.5 |
Rossari Biotech Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 650,680,000.0 | 1,374,430,000.0 | 432,550,000.0 | 1,515,580,000.0 | — |
| Investing Activities | -2,194,810,000.0 | -1,836,950,000.0 | -1,032,140,000.0 | -1,808,940,000.0 | — |
| Financing Activities | 1,863,220,000.0 | 649,010,000.0 | 161,850,000.0 | 608,550,000.0 | — |